LGND News and Press, Ligand Pharmaceuticals Incorporated From 02/26/19

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 64 Performance Each week, since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is ...

Event to feature business updates and presentations by four corporate partners Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, March 12, 2019 from 10:00 a.m. to 12:00 p.m. Eastern time (7:00 a.m. to 9:00 a.m. Pacific time) in New York City. ...

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 64 Performance Each week, since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is ...

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology looks undervalued by a bit more than 10% relative to historical avera...

Ligand Pharmaceuticals Incorporated (LGND) Q4 2018 Results Earnings Conference Call February 07, 2019, 04:30 PM ET Company Participants Todd Pettingill - Director, Corporate Development and Investor Relations John Higgins - Chief Executive Officer Matthew Foehr - President and Ch...

Ligand Pharmaceuticals (NASDAQ: LGND ) Q4 results ($M): Revenues: 59.6 (+18.0%); Royalties: 40.2 (+42.0%). More news on: Ligand Pharmaceuticals Incorporated, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Ligand Pharmaceuticals (NASDAQ: LGND ): Q4 Non-GAAP EPS of $1.70 beats by $0.48 ; GAAP EPS of -$2.02 misses by $2.92 . More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...

Conference Call Begins at 4:30 p.m. Eastern Time Today Analyst day to be held on Tuesday March 12 at 10:00 a.m. Eastern Time in New York City Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2018...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden. Under the terms of the partnership, Genagon gains access to the full OmniAb platform including...

Ligand Pharmaceuticals (NASDAQ: LGND ) is scheduled to announce Q4 earnings results on Thursday, February 7th, after market close. More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, , Healthcare stocks news, Read more ...